Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Palisade Bio Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
PALI
Nasdaq
8731
https://palisadebio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Palisade Bio Inc
Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
- May 2nd, 2024 12:30 pm
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)
- May 1st, 2024 12:30 pm
Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach
- Apr 23rd, 2024 12:30 pm
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool
- Apr 16th, 2024 12:30 pm
Palisade Bio to Participate in the Virtual Investor Lunch Break Event
- Apr 11th, 2024 1:15 pm
Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™
- Apr 10th, 2024 12:15 pm
Palisade Bio Announces 1-for-15 Reverse Stock Split
- Apr 3rd, 2024 9:30 pm
Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update
- Mar 27th, 2024 12:00 pm
Palisade Bio to Present at Digestive Disease Week (DDW) 2024
- Feb 15th, 2024 1:35 pm
Palisade Bio Provides Corporate Update and Reiterates Guidance
- Feb 13th, 2024 1:35 pm
Correction Notice of Palisade Bio’s Press Release Announcing the Appointment of Clinical Advisory Board Members
- Feb 8th, 2024 7:40 pm
Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders
- Feb 8th, 2024 1:05 pm
Palisade Bio Announces Exercise of Previously Issued Warrants for $2.5 Million
- Jan 30th, 2024 2:25 pm
Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn’s & Colitis Congress
- Jan 29th, 2024 1:05 pm
Palisade Bio Selected for Poster Presentation at the 2024 Crohn’s & Colitis Congress
- Jan 9th, 2024 1:00 pm
Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn’s and Colitis Foundation for Development of PALI-2108
- Dec 28th, 2023 1:00 pm
Palisade Bio Reports Third Quarter 2023 Financial Results and Provides Business Outlook
- Nov 10th, 2023 1:05 pm
Palisade Bio to Participate at the Virtual Investor Ask the CEO Conference
- Oct 11th, 2023 1:05 pm
Insider Buying: John Finley Acquires 15,000 Shares of Palisade Bio Inc
- Sep 14th, 2023 11:13 pm
Palisade Bio Announces Closing of $2 Million Registered Direct Offering Priced At Market Under Nasdaq Rules
- Sep 11th, 2023 8:01 pm
Scroll